Cordis set to blaze a trail in US drug-eluting stent market
This article was originally published in Clinica
Executive Summary
The first FDA approval of a drug-eluting stent (DES) is on the horizon, with Cordis' (Johnson & Johnson) Cypher sirolimus-eluting stent expected to receive the nod from the agency within the next four months.